Published in Gene Therapy Weekly, July 13th, 2000
pcTG90 is a newly designed cationic glycerolipid that binds with plasmid DNA and can efficiently deliver genes to target organs in vivo. In addition to its efficiency, this synthetic vector is attractive because it is easily manipulated and is less likely to cause the patient's immune system to mount an immune response to it than vectors containing protein...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.